TriMas Corporation — Q1 2021 Form 10-Q Summary
Business context and reporting period
TriMas designs and manufactures products serving consumer products, aerospace and defense, and industrial markets through its Packaging, Aerospace, and Specialty Products segments. The filing covers the unaudited three months ended March 31, 2021, compared with the three months ended March 31, 2020.
Financial performance and key metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $206.7 million | $182.8 million | 13.1% increase |
| Gross profit | $51.3 million | $46.4 million | 10.7% increase |
| Gross margin | 24.8% | 25.4% | 60 basis-point decline |
| Operating profit | $21.1 million | $19.8 million | 6.5% increase |
| Operating margin | 10.2% | 10.8% | 60 basis-point decline |
| Net income | $13.1 million | $13.1 million | Essentially flat |
| Diluted EPS | $0.30 | $0.30 | Flat |
| Cash flow from operations | $15.7 million | $3.4 million | Increase of $12.3 million |
| Capital expenditures | $9.4 million | $3.9 million | Increase of $5.4 million |
Packaging sales increased 32.0% to $132.1 million, supported by demand for dispensing and closure products used in hygiene applications and contributions from the Affaba & Ferrari and Rapak acquisitions. Aerospace sales declined 8.8% to $44.6 million, while Specialty Products sales declined 11.2% to $30.0 million.
At March 31, 2021, cash and cash equivalents were $421.1 million, including $410.0 million unrestricted cash and $11.2 million restricted cash. Total assets were $1.54 billion and shareholders’ equity was $596.0 million.
Total debt was $690.2 million, consisting primarily of $400.0 million of 4.125% senior notes due 2029 and $300.0 million of 4.875% senior notes due 2025, net of debt issuance costs. The company had no revolving credit borrowings outstanding and approximately $300.0 million of revolving capacity available at quarter end.
Material changes versus the prior comparable period
- Sales growth was driven primarily by Packaging, acquisitions, favorable currency translation, and higher demand for products supporting hygiene-related applications.
- Organic sales increased approximately $3.5 million; Packaging organic sales growth was partly offset by lower Aerospace and Specialty Products demand related to COVID-19.
- Raw-material costs, particularly resin and certain steel costs, increased. Management estimated that delayed recovery through pricing actions reduced first-quarter operating profit by approximately $2.0 million.
- Gross and operating margins declined despite higher profit dollars, reflecting material inflation, unfavorable product mix, acquisition-related items, and realignment costs.
- Operating cash flow improved substantially because the prior-year period included unfavorable working-capital movements and the company continued to manage receivables, inventory, and payables.
- First-quarter 2020 investing cash outflows included approximately $84.3 million for the RSA acquisition; no business acquisitions occurred in the first quarter of 2021.
- Share repurchases decreased to approximately $2.6 million in Q1 2021 from $31.6 million in Q1 2020. Approximately $159.1 million remained under the repurchase authorization.
Guidance, outlook, risks, contingencies, and unusual items
TriMas did not provide a quantified earnings or sales forecast in the filing. Management expects continued uncertainty from COVID-19, with strong demand for certain Packaging products but prolonged weakness in aerospace and uncertainty in industrial markets. Management expects lower aerospace sales and production levels to continue for the foreseeable future and may pursue additional footprint and cost actions.
The company recorded $4.1 million of pre-tax realignment charges, including approximately $1.5 million of facility-consolidation costs and $2.6 million of employee-separation costs. The actions included closing the Union City, California Packaging facility, consolidating Aerospace activities, and reorganizing the corporate legal group.
On April 15, 2021, after quarter end, TriMas redeemed its $300.0 million 2025 Senior Notes for $314.6 million, including a $7.3 million redemption premium and $7.3 million of accrued interest. The 2029 notes issuance and related refinancing extended the principal maturity profile but increased gross senior debt.
At March 31, 2021, the company reported an actual total net leverage ratio of 1.77x versus a 4.00x covenant limit and an interest coverage ratio of 12.78x versus a 3.00x requirement. The company was in compliance with its financial covenants.
TriMas reported 347 pending asbestos cases involving 4,676 claimants and total asbestos-related liabilities of $27.9 million. Management does not believe the asbestos matters will have a material adverse effect, although future claims and defense costs remain uncertain. Other ordinary-course litigation was also not expected to be material.
Principal risks include COVID-19 effects, aerospace and industrial demand weakness, raw-material inflation and supply constraints, foreign-currency volatility, leverage and debt covenant requirements, acquisition integration, impairment risk, cybersecurity, litigation, labor disruptions, and potential additional restructuring or inventory-related charges.
Important facts for investors to verify
- Whether Packaging demand for hygiene-related dispensing and closure products remains durable as pandemic-related demand normalizes.
- The pace of recovery in aerospace, industrial cylinders, and oil-and-gas-related products.
- Whether pricing actions fully recover resin, steel, and other input-cost inflation, including the reported $2.0 million first-quarter profit impact.
- The cash and debt impact of the April 2021 redemption of the 2025 notes, including the redemption premium and accrued interest.
- Progress and expected savings from the Union City, Aerospace, and corporate realignment actions, and the possibility of additional charges.
- Compliance with leverage and interest-coverage covenants after the refinancing and any future acquisitions or shareholder returns.
- Future asbestos claim activity, defense costs, and adequacy of the $27.9 million recorded liability.
- Whether operating cash flow remains sufficient to fund capital expenditures, debt service, repurchases, pension contributions, and other commitments.